Opioid Policy Research Collaborative

Publications and Relevant Research

Irvine, Michael, Oller, Declan, Boggis, Jesse, Bishop, Brian, Coombs, Daniel, Wheeler, Eliza, Doe-Simkins, Maya, Walley, Alexander, Marshall, Brandon DL, Bratberg, Jeffrey, Green, Traci. Estimating Naloxone Need in the United States Across Fentanyl, Heroin, and Prescription Opioid Epidemics: A Modelling Study (September 23, 2021). Available at SSRN: https://ssrn.com/abstract=3929585 or http://dx.doi.org/10.2139/ssrn.3929585

Clark, T.W. Determinism and Destigmatization: Mitigating Blame for Addiction. Neuroethics 14, 219–230 (2021). doi.org/10.1007/s12152-020-09440-w

Nolen S, Zang X, Chatterjee A, Behrends CN, Green TC, Kumar A, Linas BP, Morgan JP, Murphy SM, Walley AY, Yan S, Schackman BR, Marshall BDL. (2021). Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island. Addiction (Online ahead of print). doi: 10.1111/add.15759.

TC Green, D Hartung, A Irwin, J Boggis, M Gray, A Floyd, G Leichtling, D Bolivar, J Bratberg. Study Protocol for the Respond to Prevent Study: A multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies. Substance abuse Journal (in press).

Bohler RM, Hodgkin D, Kreiner PW, TC Green (2021). Predictors of U.S. States’ Adoption of Naloxone Access Laws, 2001-2017. Drug and Alcohol Dependence. 225, 108772. Published online May 21, 2021. PMCID: PMC8282714.

TC Green, T Stopka, Z Xuan, TC Davis, J Boggis, AN Irwin, M Gray, DM Hartung, J Bratberg. Examining nonprescription syringe sales in Massachusetts and Rhode Island community pharmacies. Journal of the American Pharmacists Association. 2021 Mar 11;S1544-3191(21)00102-3. doi: 10.1016/j.japh.2021.03.004. PMID: 33820716

Green, TC., Bratberg, J., Baird, J., Burstein, D., Lenz, K., Case, P., Walley, AY., Xuan, Z. Rurality and differences in pharmacy characteristics and community factors associated with provision of naloxone in the pharmacy. Int J Drug Policy. 2020 Nov 15;102602. PMID: 31740174 . doi: 10.1016/j.drugpo.2019.11.010

TC Green, C Davis, Z Xuan, AY Walley, J Bratberg (2020). Laws Mandating Coprescription of Naloxone and Their Impact on Naloxone Prescription in Five US States, 2014–2018. American Journal of Public Health 110(6):881-887. doi: 10.2105/AJPH.2020.305620. PMCID: PMC7204438

TC Green, E Donovan, B Klug, P Case, J Baird, A Tapper, A Walley, J Bratberg. Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in two states: 2017 perspectives and evolving approaches. Journal of the American Pharmacists Association 2020 Apr 22;S1544-3191(20)30119-9. doi: 10.1016/j.japh.2020.03.005. PMID: 32334964

E Donovan, J Baird, D Burstein, P Case, AY Walley, J Bratberg, TC Green. Pharmacy leaders’ beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community. Research in Social and Administrative Pharmacy 2020, Oct;16(10):1493-1497. doi: 10.1016/j.sapharm.2020.01.006. PMID: 31983625

D Burstein, J Baird, J Bratberg, E Donovan, E Soipe, A Tapper, P Case, A Walley, TC Green. (2019). Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study. Journal of the American Pharmacists Association. Mar-Apr 2020;60(2):304-310. doi: 10.1016/j.japh.2019.11.004. PMID: 31870862

TC Green, A Soipe, B Baloy, D Burstein, Z Xuan, A Tapper, AY Walley, P Case, J Bratberg & J Baird. Pharmacy on-site overdose protocols and prevention of overdose. Substance Abuse,(2020) PMID: 32186478 https://doi.org/10.1080/08897077.2020.1736236

Strickler GK, Kreiner PW, Halpin JF, Doyle E, Paulozzi LJ. (2020) Opioid Prescribing Behaviors - Prescription Behavior Surveillance System, 11 States, 2010-2016. Published in the Centers for Disease Control’s Morbidity and Mortality Weekly Report Surveillance Summary, 69(1), 1-14. doi:10.15585/mmwr.ss6901a1.

Strickler GK, Zhang K, Halpin JF, Bohnert ASB, Baldwin GT, Kreiner PW. (2019) Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing. Drug Alcohol Depend, 199:1‐9. doi:10.1016/j.drugalcdep.2019.02.010

Strickler GK, Kreiner PW, Halpin JF, Doyle E, Paulozzi LJ (2019). Opioid Prescribing Behaviors — Prescription Behavior Surveillance System, 11 States, 2010–2016. MMWR Surveillance Summary, 69(1);1–14. doi: http://dx.doi.org/10.15585/mmwr.ss6901a1external icon